中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(9): 2146-2149

Influence of small intestinal bacterial overgrowth on liver cirrhosis and its treatment

DOI: 10.3969/j.issn.1001-5256.2022.09.038

  • Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang 050035, China

Research funding:

Medical Science Research Project of Hebei Province (20220117);

Postgraduate Innovation Funding Project of Hebei Province (CXZZBS2020112)

More Information
  • Corresponding author: ZHANG Xiaolan, xiaolanzh@126.com(ORCID: 0000-0002-7047-3634)
  • Received Date: 2022-02-20
  • Accepted Date: 2022-04-02
  • Published Date: 2022-09-20
    Abstract
  • Small intestinal bacterial overgrowth (SIBO) is characterized by changes in the number or species of small intestinal flora. Patients with liver cirrhosis often have intestinal congestion, edema, and delayed peristalsis and develop SIBO, which can further aggravate intestinal abnormalities. In patients with liver cirrhosis, SIBO can lead to significant adverse clinical outcomes, and since the increase in intestinal permeability may cause bacterial translocation into systemic circulation, SIBO is considered an important risk factor in the pathogenesis of liver cirrhosis, spontaneous bacterial peritonitis, and hepatic encephalopathy. Antibiotics, especially rifaximin, are the most effective therapies for SIBO, and in addition, studies are being conducted to investigate the efficacy of potential therapies such as prokinetic agents, probiotics, non-selective β-receptor blocker, and liver transplantation.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    DRASAR BS, SHINER M. Studies on the intestinal flora. Ⅱ. Bacterial flora of the small intestine in patients with gastrointestinal disorders[J]. Gut, 1969, 10(10): 812-819. DOI: 10.1136/gut.10.10.812.
    [2]
    GUO XX, HU N, LIAN XX. Features of intestinal flora imbalance in patients with liver cirrhosis and related driving factors[J]. J Clin Hepatol, 2020, 36(7): 1527-1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016.

    郭晓霞, 胡娜, 廉晓晓. 肝硬化患者肠道菌群失调的特征及驱动因子分析[J]. 临床肝胆病杂志, 2020, 36(7): 1527-1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016.
    [3]
    WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60(1): 197-209. DOI: 10.1016/j.jhep.2013.07.044.
    [4]
    SCARPELLINI E, ABENAVOLI L, CASSANO V, et al. The apparent asymmetrical relationship between small bowel bacterial overgrowth, endotoxemia, and liver steatosis and fibrosis in cirrhotic and non-cirrhotic patients: A single-center pilot study[J]. Front Med (Lausanne), 2022, 9: 872428. DOI: 10.3389/fmed.2022.872428.
    [5]
    GURUSAMY SR, SHAH A, TALLEY NJ, et al. Small intestinal bacterial overgrowth in functional dyspepsia: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2021, 116(5): 935-942. DOI: 10.14309/ajg.0000000000001197.
    [6]
    GALLOWAY D, MEZOFF E, ZHANG W, et al. Serum unconjugated bile acids and small bowel bacterial overgrowth in pediatric intestinal failure: A pilot study[J]. JPEN J Parenter Enteral Nutr, 2019, 43(2): 263-270. DOI: 10.1002/jpen.1316.
    [7]
    CORAZZA GR, MENOZZI MG, STROCCHI A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing[J]. Gastroenterology, 1990, 98(2): 302-309. DOI: 10.1016/0016-5085(90)90818-l.
    [8]
    REZAIE A, BURESI M, LEMBO A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus[J]. Am J Gastroenterol, 2017, 112(5): 775-784. DOI: 10.1038/ajg.2017.46.
    [9]
    MADIGAN KE, BUNDY R, WEINBERG RB. Distinctive clinical correlates of small intestinal bacterial overgrowth with methanogens[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.09.035.[Online ahead of print]
    [10]
    RICHARD N, DESPREZ C, WUESTENBERGHS F, et al. The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth[J]. United European Gastroenterol J, 2021, 9(6): 645-654. DOI: 10.1002/ueg2.12116.
    [11]
    SHAH A, SHANAHAN E, MACDONALD GA, et al. Systematic review and meta-analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease[J]. Semin Liver Dis, 2017, 37(4): 388-400. DOI: 10.1055/s-0037-1608832.
    [12]
    CIRERA I, BAUER TM, NAVASA M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis[J]. J Hepatol, 2001, 34(1): 32-37. DOI: 10.1016/s0168-8278(00)00013-1.
    [13]
    MIELE L, VALENZA V, LA TORRE G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease[J]. Hepatology, 2009, 49(6): 1877-1887. DOI: 10.1002/hep.22848.
    [14]
    ZHOU YJ. Gut microbiota and liver cirrhosis[J]. J Prac Hepatol, 2016, 19(2): 139-142. DOI: 10.3969/j.issn.1672-5069.2016.02.004.

    周永健. 肠道微生态与肝硬化[J]. 实用肝脏病杂志, 2016, 19(2): 139-142. DOI: 10.3969/j.issn.1672-5069.2016.02.004.
    [15]
    KHAN A, DING Z, ISHAQ M, et al. Understanding the effects of gut microbiota dysbiosis on nonalcoholic fatty liver disease and the possible probiotics role: recent updates[J]. Int J Biol Sci, 2021, 17(3): 818-833. DOI: 10.7150/ijbs.56214.
    [16]
    MAN S, YANG L, XIANG H, et al. Antihypertensive and renal protective effect of Shunaoxin pill combined with captopril on spontaneous hypertension rats[J]. Biomed Pharmacother, 2020, 125: 109977. DOI: 10.1016/j.biopha.2020.109977.
    [17]
    CHEUNG A, TANNA S, ISON MG. Infectious complications in critically ill liver failure patients[J]. Semin Respir Crit Care Med, 2018, 39(5): 578-587. DOI: 10.1055/s-0038-1673657.
    [18]
    HOLVAST A, KATS-UGURLU G, BODEWES F, et al. Reversal of secondary protein-losing enteropathy after surgical revision of a jejunal Roux-en-Y loop in a patient after liver transplantation[J]. Am J Transplant, 2019, 19(7): 2116-2121. DOI: 10.1111/ajt.15354.
    [19]
    ABID S, KAMRAN M, ABID A, et al. Minimal hepatic encephalopathy: Effect of H. pylori infection and small intestinal bacterial overgrowth treatment on clinical outcomes[J]. Sci Rep, 2020, 10(1): 10079. DOI: 10.1038/s41598-020-67171-7.
    [20]
    GHOSH G, JESUDIAN AB. Small intestinal bacterial overgrowth in patients with cirrhosis[J]. J Clin Exp Hepatol, 2019, 9(2): 257-267. DOI: 10.1016/j.jceh.2018.08.006.
    [21]
    SOUTO PA, MARCOTEGUI AR, ORBEA L, et al. Hepatic encephalopathy: Ever closer to its big bang[J]. World J Gastroenterol, 2016, 22(42): 9251-9256. DOI: 10.3748/wjg.v22.i42.9251.
    [22]
    ZHANG Y, FENG Y, CAO B, et al. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis[J]. Arch Med Sci, 2016, 12(3): 592-596. DOI: 10.5114/aoms.2015.55675.
    [23]
    GUNNARSDOTTIR SA, SADIK R, SHEV S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension[J]. Am J Gastroenterol, 2003, 98(6): 1362-1370. DOI: 10.1111/j.1572-0241.2003.07475.x.
    [24]
    STEINGERDUR AG, RIADH S, STEVEN S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension[J]. Am J Gastroenterol, 2003, 98(6): 1362-1370. DOI: 10.1016/S0002-9270(03)00250-8.
    [25]
    MASLENNIKOV R, PAVLOV C, IVASHKIN V. Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis[J]. Hepatol Int, 2018, 12(6): 567-576. DOI: 10.1007/s12072-018-9898-2.
    [26]
    CAO LT, SUN JY, LI CY, et al. Advances in research on cirrhosis and small intestinal bacterial overgrowth[J]. J Ningxia Med Univ, 2021, 43(8): 870-875. DOI: 10.16050/j.cnki.issn1674-6309.

    曹莉婷, 孙瑾瑜, 李初谊, 等. 肝硬化与小肠细菌过度生长的研究进展[J]. 宁夏医科大学学报, 2021, 43(8): 870-875. DOI: 10.16050/j.cnki.issn1674-6309.
    [27]
    RAMACHANDRAN A, PRABHU R, THOMAS S, et al. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals[J]. Hepatology, 2002, 35(3): 622-629. DOI: 10.1053/jhep.2002.31656.
    [28]
    JIA FZ. Hepatopathy and intestinal microecology environment[J]. Chin J Pract Int Med, 2006, 26(13): 971-974. DOI: 10.3969/j.issn.1005-2194.2006.13.005.

    贾辅忠. 肝病与肠道微生态环境[J]. 中国实用内科学杂志, 2006, 26(13): 971-974. DOI: 10.3969/j.issn.1005-2194.2006.13.005.
    [29]
    MOUILLOT T, RHYMAN N, GAUTHIER C, et al. Study of small intestinal bacterial overgrowth in a cohort of patients with abdominal symptoms who underwent bariatric surgery[J]. Obes Surg, 2020, 30(6): 2331-2337. DOI: 10.1007/s11695-020-04477-5.
    [30]
    RAO S, BHAGATWALA J. Small intestinal bacterial overgrowth: clinical features and therapeutic management[J]. Clin Transl Gastroenterol, 2019, 10(10): e00078. DOI: 10.14309/ctg.0000000000000078.
    [31]
    LIU ZJ, DUAN LP. Advances in research on small intestinal bacterial overgrowth[J]. Chin J Child Health Care, 2017, 25(8): 793-833. DOI: 10.11852/zgetbjzz2017-25-08-11.

    刘作静, 段丽萍. 小肠细菌过度生长研究进展[J]. 中国儿童保健杂志, 2017, 25(8): 793-833. DOI: 10.11852/zgetbjzz2017-25-08-11.
    [32]
    ZENG X, SHENG X, WANG PQ, et al. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis[J]. Hepatol Int, 2021, 15(1): 155-165. DOI: 10.1007/s12072-020-10117-y.
    [33]
    CHOJNACKI C, POPLAWSKI T, KONRAD P, et al. Serotonin pathway of tryptophan metabolism in small intestinal bacterial overgrowth-A pilot study with patients diagnosed with lactulose hydrogen breath test and treated with rifaximin[J]. J Clin Med, 2021, 10(10): 2065. DOI: 10.3390/jcm10102065.
    [34]
    ZHUANG X, TIAN Z, LUO M, et al. Short-course rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome[J]. BMC Gastroenterol, 2020, 20(1): 187. DOI: 10.1186/s12876-020-01336-6.
    [35]
    KANG SH, LEE YB, LEE JH, et al. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy[J]. Aliment Pharmacol Ther, 2017, 46(9): 845-855. DOI: 10.1111/apt.14275.
    [36]
    FURNARI M, DE ALESSANDRI A, CRESTA F, et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin[J]. J Gastroenterol, 2019, 54(3): 261-270. DOI: 10.1007/s00535-018-1509-4.
    [37]
    FUKUI H. Leaky gut and gut-liver axis in liver cirrhosis: Clinical studies update[J]. Gut Liver, 2021, 15(5): 666-676. DOI: 10.5009/gnl20032.
    [38]
    NOURI GHARAJALAR S, KAZEMI-DARABADI S, VALINEZHAD LAJIMI H, et al. The roles of lactobacillus acidophilus and pectin in preventing postoperative sepsis and intestinal adaptation in a rat model of short bowel syndrome[J]. Probiotics Antimicrob Proteins, 2021, 13(5): 1355-1362. DOI: 10.1007/s12602-021-09764-w.
    [39]
    SENZOLO M, CHOLONGITAS E, BURRA P, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis[J]. Liver Int, 2009, 29(8): 1189-1193. DOI: 10.1111/j.1478-3231.2009.02038.x.
    [40]
    REIBERGER T, FERLITSCH A, PAYER BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J]. J Hepatol, 2013, 58(5): 911-921. DOI: 10.1016/j.jhep.2012.12.011.
    [41]
    SHI H, MAO L, WANG L, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol, 2021, 33(1S Suppl 1): e535-e539. DOI: 10.1097/MEG.0000000000002157.
    [42]
    HAMMER HF, FOX MR, KELLER J, et al. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus[J]. United European Gastroenterol J, 2022, 10(1): 15-40. DOI: 10.1002/ueg2.12133.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (572) PDF downloads(40) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return